Tecemotide May Be Effective in NSCLC with Concurrent Chemoradiotherapy

Share this content:
Tecemotide may provide treatment benefit in stage III NSCLC treated with concurrent chemoradiotherapy.
Tecemotide may provide treatment benefit in stage III NSCLC treated with concurrent chemoradiotherapy.

According to a new study published online in the journal Annals of Oncology, researchers have found that tecemotide, a MUC1-antigen-specific cancer immunotherapy, may provide treatment benefit in patients with stage III non-small cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy.

Researchers had previously conducted the phase III START study that evaluated tecemotide versus placebo, and although the study did not meet its primary endpoint, a subgroup analysis found that tecemotide provided notable survival benefit versus placebo in patients treated with concurrent radiotherapy.

Now, the researchers report updated overall survival data in patients with unresectable stage III NSCLC who had not progressed following frontline chemoradiotherapy and had been treated with tecemotide or placebo during the START trial.

RELATED: Opdivo Approved for Advanced Squamous Non-Small Cell Lung Cancer

Results showed that median overall survival was 25.8 months in the tecemotide group versus 22.4 months in the placebo group (HR = 0.89; 95% CI: 0.77 - 1.03; P = 0.111) with about 20 months of additional median follow-up time compared with the primary analysis in the START trial.

The exploratory subgroup analysis had shown an overall survival of 29.4 months in the tecemotide group compared with 20.8 months in the placebo group (HR = 0.81; 95% CI: 0.68 - 0.98; P = 0.026). Researchers also found that elevated sMUC1 or ANA levels may correlate with tecemotide benefit.

Reference

  1. Mitchell P, Thatcher N, Socinski MA, et al. Tecemotide in unresectable stage III non-small cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv104.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters